Received Sep 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | — | IM |
afib; This spontaneous case was reported by a consumer and describes the occurrence of ATRIAL FIBRILLATION (afib) in an 87-year-old male patient who received SPIKEVAX NOS (SPIKEVAX NOS) for COVID-19 prophylaxis. Concurrent medical conditions included Emphysema. On an unknown date, the patient received dose of SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) 1 dosage form. On an unknown date, the patient experienced ATRIAL FIBRILLATION (afib) (seriousness criterion medically significant). At the time of the report, ATRIAL FIBRILLATION (afib) outcome was unknown. The action taken with SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) was unknown. Concomitant medication was not reported. It was reported that a patient visited his GP who had been his doctor for the past 10 years and was advised not to receive any COVID-19 vaccine this year. He received twice a year, and from the start of COVID in 2019-2020 he had taken Moderna shots every time. Patient's GP told him that what was happening was that the COVID shot was metastasizing, it was mentioned that this might be the incorrect word, with the previous shots and could cause their own little malady that affects the heart and lungs. It was reported that, patient was inquiring whether he should receive a COVID-19 vaccine. Patient suffered from emphysema and had been receiving Moderna's COVID-19 vaccines in recent years. Patient's doctor informed him that receiving a COVID-19 vaccine this year could potentially exacerbate his condition and create complications. It was unknown if the patient experienced any additional symptoms/events. Treatment medication was not reported. Reporter did not allow further contact Most recent FOLLOW-UP information incorporated above includes: On 18-Sep-2025: Live significant follow-up received: Reporter name, medical history and reference id added; Reporter's Comments: The benefit -risk relationship of product is not affected by this report.
Emphysema